Implementing whole genome and transcriptome sequencing for cancer patients in routine healthcare: a comprehensive guide to costing

Key Points

The aim is to explore the adoption of whole genome sequencing (WGS) and transcriptome sequencing (WTS) as routine healthcare practices for cancer patients.
Reviewing cost structures of WGS/WTS tests
Analyzing the current pricing of consumables
Assessing clinical implementation processes
Lower costs of consumables are likely to improve adoption rates of WGS/WTS
WGS/WTS can be integrated into clinical settings more feasibly
Potential enhancement of personalized cancer treatment options

This guide demonstrates the implementation of WGS/WTS in cancer healthcare, suggesting that lower costs enhance feasibility.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Altbürger et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share